CN1282585A - Compound necleotide preparation - Google Patents
Compound necleotide preparation Download PDFInfo
- Publication number
- CN1282585A CN1282585A CN 00110727 CN00110727A CN1282585A CN 1282585 A CN1282585 A CN 1282585A CN 00110727 CN00110727 CN 00110727 CN 00110727 A CN00110727 A CN 00110727A CN 1282585 A CN1282585 A CN 1282585A
- Authority
- CN
- China
- Prior art keywords
- acid
- guanyl
- uridylic
- cytidylic
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composite neucleotide preparation for supplementing and reparing human damaged cell and gene and improving immunity contains adenyl acid 5-AMP, guanylic acid 5'-GMP, uridylic acid 5'-UMP and cytidylic acid 5'-CMP in weight ratio of (1.4-1.8):(0.9-1.2):(1.1-1.6):(0.9-1.3). Its advantage is high effect.
Description
The present invention is a kind of biological preparation, is a kind of gene nutrient specifically, promptly a kind of compound nucleotide preparation, and it belongs to medicine or nutritive health products.
Along with the develop rapidly of science and technology, orthomolecular medicine obtains significant progress.The thing followed is the appearance of range gene nutrient, wherein is mainly various nucleic acid preparations.By oral or injection nucleic acid preparation, to remedy the damaged and not enough of human body nucleic acid.But now the problem that exists is: the gene nutrient of selling on the market all is a nucleic acid product now, because nucleic acid belongs to macromolecular structure, enters in the cell so its is difficult for being absorbed by gastrointestinal, and is undesirable for additional damaged effect with the repair cell gene.
The purpose of this invention is to provide a kind of novel gene nutrient, it can overcome existing shortcoming in the prior art, has effect preferably for replenishing with the damaged of repair cell and improving immune function of human body.
The object of the present invention is achieved like this: it mainly is made up of adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP, and the ratio of the parts by weight between each composition is: adenylic acid: guanyl: uridylic acid: cytidylic acid=1.4～1.8: 0.9～1.2: 1.1～1.6: 0.9～1.3.
Its Main Ingredients and Appearance also can include only any three kinds in above-mentioned four kinds of compositions, and the ratio of the parts by weight between each composition still remains unchanged.
The present invention is except that above-mentioned Main Ingredients and Appearance, and other less important composition also includes the trace element of various needed by human, as auxiliary material such as ferrum, calcium etc. and solvent, binding agents.
The present invention is made of multiple nucleotide, is to be raw material with the plant nucleic acid, extracts through technologies such as fermentation, enzymolysis, centrifugal and ultrafiltration to form, and its molecular formula is respectively: adenylic acid C
6H
14N
9O
7P, guanyl C
6H
12N
5O
8P, uridylic acid C
5H
13N
2O
9P, cytidylic acid C
5H
14N
2O
8P, the molecular weight of nucleotide is little, can enter cell, be easy to be absorbed by human body, according to human body needs repair cell and impaired gene voluntarily,, has ideal effect equally for improving immune function of human body so have effect preferably for replenishing and repair the damaged gene of human body.
Learn assessment process and method according to the health protection food function, Liaoning Province Food Hygiene Surveillance check to " immunoregulation effect " animal experiment that the present invention did, assay proves: (oral liquid is with the ion water as solvent for submitted sample, contain compound nucleotide preparation 2mg of the present invention in every milliliter of ionized water), have the nonspecific immunity of enhancing and cellular immunization and humoral immune function.Human clinical experiment be used for because put, due to the chemotherapy leukopenia to WBC2.7 * 10
9/ L took the above-mentioned oral liquid of the present invention 6 days, and leukocyte rises to 5.7 * 10
9/ L, immunologic function obviously improves.In addition, World Health Organization (WHO) is published in the developed country, and nucleotide content is that l00ml contains 2.3-2.9mg in the breast milk.The content of nucleotide only was 1.19mg in the breast milk first in the Shanghai sampling observation in 1999 in China.The testing result in Liaoning Province is then lower, has only 0.9～1.0mg.One group of postpartum women is carried out the contrast of multiplexing front and back, and obeying content every day is the oral liquid 10ml of 2.0mg/ml, and nucleotide content begins to improve in 5 days later breast milks, illustrates that the present invention has a significant effect for the content that improves human body nucleotide.
The present invention is further detailed explanation below in conjunction with embodiment.
Embodiment one
At first adopting plant nucleic acid is raw material, extract adenylic acid 5 ＇-AMP, guanyl 6 ＇-GMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP with technologies such as fermentation, enzymolysis, centrifugal, ultrafiltration, with above-mentioned composition according to 1.6: 1: 1.3: 1 parts by weight mix, make compound nucleotide, with the ionized water is solvent, contain 2 milligrams of compound nucleotides in every milliliter, sooner or later respectively take 10 milliliters every day, or increase and decrease consumption as required.
Embodiment two
Adopt above-mentioned raw materials and technology to extract guanyl 6 ＇-GMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP, parts by weight with 1.2: 1.6: 1.3 are mixed and made into compound nucleotide, adopt common process to make granule, encapsulated, take the 20-40 milligram every day.
Embodiment three
Adopt above-mentioned raw materials and technology to extract adenylic acid 5 ＇-AMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP, mix, make compound nucleotide, adopt common process to make tablet, take by above-mentioned amount according to 1.8: 1.4: 1 parts by weight preparations.
Embodiment four
Adopt above-mentioned raw materials and technology to extract adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, cytidylic acid 5 ＇-CMP,, adopt common process to make tablet, take according to above-mentioned consumption according to 1.4: 0.9: 0.9 parts by weight mixed preparing compound nucleotide.
Embodiment five
Adopt above-mentioned raw materials and technology to extract adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, uridylic acid 5 ＇-UMP, ratio preparation compound nucleotide according to 1.2: 1: 1.1 parts by weight, with the ion water as solvent, every milliliter contains 2 milligrams of compound nucleotides, 10 milligrams every liter of calcics, 1 milligram every liter of iron content, add an amount of sugar in addition, to transfer taste, 20 milliliters of every days, divide secondary to take.
Claims (5)
1, a kind of compound nucleotide preparation, it is characterized in that it mainly is made up of adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP, the ratio of the parts by weight between each composition is: adenylic acid: guanyl: uridylic acid: cytidylic acid=1.4～1.8: 0.9～1.2: 1.1～1.6: 0.9～1.3.
2, according to the said compound nucleotide preparation of claim 1, it is characterized in that its Main Ingredients and Appearance is that guanyl 5 ＇-GMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP form, the ratio of the parts by weight between each composition is: guanyl: uridylic acid: cytidylic acid=0.9～1.2: 1.1～1.6: 0.9～1.3.
3, according to the said compound nucleotide preparation of claim 1, it is characterized in that adenylic acid 5 ＇-AMP, uridylic acid 5 ＇-UMP, cytidylic acid 5 ＇-CMP form, the ratio of the parts by weight between each composition is: adenylic acid: uridylic acid: cytidylic acid=1.4～1.8: 1.1～1.6: 0.9～1.3.
4, according to the said nucleotide preparation of claim 1, it is characterized in that adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, cytidylic acid 5 ＇-CMP form, the ratio of the parts by weight between each composition is: adenylic acid: guanyl: cytidylic acid=1.4～1.8: 0.9～1.2: 0.9～1.3.
5, according to the said nucleotide preparation of claim 1, it is characterized in that adenylic acid 5 ＇-AMP, guanyl 5 ＇-GMP, uridylic acid 5 ＇-UMP form, the ratio of the parts by weight between each composition is: adenylic acid: guanyl: uridylic acid=1.4～1.8: 0.9～1.2: 1.1～1.6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110727 CN1282585A (en) | 2000-07-25 | 2000-07-25 | Compound necleotide preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110727 CN1282585A (en) | 2000-07-25 | 2000-07-25 | Compound necleotide preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1282585A true CN1282585A (en) | 2001-02-07 |
Family
ID=4580706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00110727 Pending CN1282585A (en) | 2000-07-25 | 2000-07-25 | Compound necleotide preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1282585A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141812A1 (en) * | 2015-03-06 | 2016-09-15 | 内蒙古伊利实业集团股份有限公司 | Nucleotide composition and application in food thereof |
| CN107712345A (en) * | 2017-10-17 | 2018-02-23 | 南京工业大学 | A kind of mixture of ribonucleotides crystal powder and preparation method thereof |
-
2000
- 2000-07-25 CN CN 00110727 patent/CN1282585A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141812A1 (en) * | 2015-03-06 | 2016-09-15 | 内蒙古伊利实业集团股份有限公司 | Nucleotide composition and application in food thereof |
| CN107529809A (en) * | 2015-03-06 | 2018-01-02 | 内蒙古伊利实业集团股份有限公司 | Polynucleotide composition and its application in food |
| CN107529809B (en) * | 2015-03-06 | 2020-03-13 | 内蒙古伊利实业集团股份有限公司 | Nucleotide composition and application thereof in food |
| CN107712345A (en) * | 2017-10-17 | 2018-02-23 | 南京工业大学 | A kind of mixture of ribonucleotides crystal powder and preparation method thereof |
| CN107712345B (en) * | 2017-10-17 | 2022-03-22 | 南京工业大学 | Nucleotide mixture crystal powder and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103037879B (en) | The preparation method that Tiny Panax ginseng saponin constituent obtains novel processed ginseng or the processed ginseng extract increased | |
| US9427452B2 (en) | Method for preparing fermentation broth of fruits and vegetables | |
| CN102242044B (en) | Cordyceps cicadae wine and preparation method thereof | |
| CN107441501A (en) | Drug-loaded liposome of antibacterial peptide modification and its production and use | |
| CN102669669B (en) | Deer spleen extract preparation and preparation method thereof | |
| JP2016539184A (en) | Algal extract for use as an immunomodulator | |
| CN101543259A (en) | Preparation method of biological feed additive | |
| CN1861581A (en) | Preparation of allantoin and allantoin extract from cistanche salsa and their use thereof | |
| CN101797023A (en) | Application of L-arabinopyranose as dealcoholic agent | |
| CN101225361A (en) | Golden fungus fermentation liquor or sesquiterpenes produced by fermentation of golden fungus liquid | |
| CN102273710A (en) | Health-care drink for enriching blood | |
| CN1064233C (en) | Polynucleotide nutrient product and its preparing process | |
| CN103113489B (en) | Method of purifying polysaccharide of Xinjiang jun dates | |
| CN101263840A (en) | Milk powder containing ribose and preparation thereof | |
| CN1282585A (en) | Compound necleotide preparation | |
| CN101721427B (en) | Method for preparing gallinaceous Newcastle disease transspecific factor | |
| CN103349079B (en) | A kind of production method of functional milk beverage with cepe | |
| CN101271089B (en) | Method for identifying allantoin in Cistanche plant variety | |
| CN102755320B (en) | pharmaceutical composition and health food for treating arthritis | |
| CN1036783C (en) | Production Technology for extracting nuclear acid from natural plant cells | |
| CN102295677A (en) | New nortriterpenoid saponin of Salicornia bigelovii Torr., preparation method and application thereof | |
| CN104928329B (en) | A kind of Sargassum horneri polysaccharide zymolyte and its application | |
| CN104982534A (en) | Ganoderma lucidum polysaccharide-containing infant formula milk powder | |
| CN105285623B (en) | Health-care beverage with function of improving immunity and making method of health-care beverage | |
| CN1146915A (en) | Compound anticancer, its preparing process and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING LONGXINGSHENG BIOLOGICAL TECHNOLOGY CO.,L Free format text: FORMER OWNER: XU ZHENYA Effective date: 20010816 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20010816 Address after: 100021 room 310, Huatai Hotel, Chaoyang District, Beijing, Jinsong, Li Jingang Applicant after: Beijing dragon prosperous Biological Technology Co., Ltd. Address before: 6, 110024, heavy street, Tiexi District, Liaoning, Shenyang Applicant before: Xu Zhenya |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |